Please use this identifier to cite or link to this item: https://doi.org/10.3389/fendo.2021.609110
DC FieldValue
dc.titleGlucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis
dc.contributor.authorWong, Chloe
dc.contributor.authorLee, Ming Hui
dc.contributor.authorYaow, Clyve Yu Leon
dc.contributor.authorChin, Yip Han
dc.contributor.authorGoh, Xin Lei
dc.contributor.authorNg, Cheng Han
dc.contributor.authorLim, Amanda Yuan Ling
dc.contributor.authorMuthiah, Mark Dhinesh
dc.contributor.authorKhoo, Chin Meng
dc.date.accessioned2021-11-15T01:59:35Z
dc.date.available2021-11-15T01:59:35Z
dc.date.issued2021-04-09
dc.identifier.citationWong, Chloe, Lee, Ming Hui, Yaow, Clyve Yu Leon, Chin, Yip Han, Goh, Xin Lei, Ng, Cheng Han, Lim, Amanda Yuan Ling, Muthiah, Mark Dhinesh, Khoo, Chin Meng (2021-04-09). Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis. FRONTIERS IN ENDOCRINOLOGY 12. ScholarBank@NUS Repository. https://doi.org/10.3389/fendo.2021.609110
dc.identifier.issn16642392
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/206120
dc.description.abstractObjective: Non-alcoholic fatty liver disease is highly prevalent in patients with type 2 diabetes mellitus. Studies on glucagon-like peptide-1 receptor agonists for the treatment of non-alcoholic fatty liver disease have reported promising results. Despite this, there has been limited evidence of its efficacy in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus. This meta-analysis examined existing evidence on the efficacy of glucagon-like peptide-1 receptor agonists on the management of non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Methods: Medline, Embase and Cochrane Central Register of Controlled Trials (CENTRAL) were searched for articles discussing the efficacy of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Values of standardized mean differences (SMD) and risk ratio (RR) were determined for continuous outcomes and dichotomous outcomes respectively. Results: 8 studies involving 1,454 patients from 5 randomized controlled trials and 3 cohort studies were included in the analysis. Our analysis found significant improvements in hepatic fat content, liver biochemistry, body composition, glucose parameters, lipid parameters, insulin sensitivity and inflammatory markers following glucagon-like peptide-1 receptor agonist treatment. Glucagon-like peptide-1 receptor agonists significantly decreased hepatic fat content compared to metformin and insulin-based therapies. Glucagon-like peptide-1 receptor agonists also improved fibrosis markers, but this did not reach statistical significance. Conclusion: With a high prevalence of obesity and non-alcoholic fatty liver disease among patients with type 2 diabetes mellitus, glucagon-like peptide-1 receptor agonist treatment shows promise in improving both diabetes and non-alcoholic fatty liver disease phenotype.
dc.language.isoen
dc.publisherFRONTIERS MEDIA SA
dc.sourceElements
dc.subjectScience & Technology
dc.subjectLife Sciences & Biomedicine
dc.subjectEndocrinology & Metabolism
dc.subjectglucagon-like peptide-1 receptor agonist
dc.subjectnon-alcoholic fatty liver disease
dc.subjecttype 2 diabetes mellitus
dc.subjectGLP-1RA
dc.subjectmeta-analysis
dc.typeReview
dc.date.updated2021-11-15T01:24:21Z
dc.contributor.departmentDUKE-NUS MEDICAL SCHOOL
dc.description.doi10.3389/fendo.2021.609110
dc.description.sourcetitleFRONTIERS IN ENDOCRINOLOGY
dc.description.volume12
dc.published.statePublished
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes A Meta-Analysis.pdf1.05 MBAdobe PDF

OPEN

PublishedView/Download

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.